[A21-92] Avelumab (urothelial carcinoma) - Addendum to Commission A21-23
Last updated 19.08.2021
Project no.:
A21-92
Commission:
Commission awarded on 09.07.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy
Result of dossier assessment:
Indication of minor added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-23 | Avelumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-08-19 A G-BA decision was published.